Potential effect of recombinant thrombomodulin on ischemia–reperfusion liver injury in rats

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Hepatology Research

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/hepr.13005PMID 29168258
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sinusoidal communication in liver fibrosis and regeneration.

  2016cited by this paper
• Ischemia-Reperfusion Injury in Fatty Liver Is Mediated by Activated NADPH Oxidase 2 in Rats

  2016cited by this paper
• Innate Immune Regulations and Liver Ischemia-Reperfusion Injury.

  2016cited by this paper
• Efficacy of recombinant thrombomodulin for DIC after deceased donor liver transplantation: a case report

  2016cited by this paper
• Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice

  2015cited by this paper
• Clinical evaluation of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation

  2014cited by this paper
• Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection

  2013cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*

  2013cited by this paper
• Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis

  2013cited by this paper
• Systemic Involvement of High-Mobility Group Box 1 Protein and Therapeutic Effect of Anti–High-Mobility Group Box 1 Protein Antibody in a Rat Model of Crush Injury

  2012cited by this paper
• Liver Ischemia and Reperfusion Injury: New Insights into Mechanisms of Innate—Adaptive Immune‐Mediated Tissue Inflammation

  2011influential reference
• Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study

  2011cited by this paper
• RECOMBINANT THROMBOMODULIN PREVENTS HEATSTROKE BY INHIBITION OF HIGH-MOBILITY GROUP BOX 1 PROTEIN IN SERA OF RATS

  2010cited by this paper
• Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia

  2009cited by this paper
• The interactions between inflammation and coagulation

  2005cited by this paper
• The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism.

  2005cited by this paper
• The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion

  2005influential reference
• Release of chromatin protein HMGB1 by necrotic cells triggers inflammation

  2002cited by this paper
• The nuclear protein HMGB1 is secreted by monocytes via a non‐classical, vesicle‐mediated secretory pathway

  2002cited by this paper
• Hepatoimmunology: A perspective

  2002cited by this paper
• Cytokines in the liver.

  2001cited by this paper
• The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses.

  2001cited by this paper
• Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes.

  1999cited by this paper
• The Inhibitory Effect of Recombinant Human Soluble Thrombomodulin on Initiation and Extension of Coagulation

  1999cited by this paper
• HMG-1 as a late mediator of endotoxin lethality in mice.

  1999cited by this paper
• Cytokines and the hepatic acute phase response

  1997cited by this paper
• Inhibition of thromboxane A2 activity during warm ischemia of the liver.

  1996cited by this paper
• Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester.

  1994cited by this paper
• The regulation of natural anticoagulant pathways

  1987cited by this paper

• Thrombomodulin-mediated Inhibition of Neutrophil Extracellular Trap Formation Alleviates Hepatic Ischemia-reperfusion Injury by Blocking TLR4 in Rats Subjected to Liver Transplantation

  2021influential citation
• The lectin‐like domain of thrombomodulin is a drug candidate for both prophylaxis and treatment of liver ischemia and reperfusion injury in mice

  2020cites this paper
• The Impact of Dabigatran Treatment on Sinusoidal Protection Against Hepatic Ischemia/Reperfusion Injury in Mice

  2020influential citation
• University of Groningen Plasma from Patients Undergoing Liver Transplantation Is Resistant to Anticoagulant Activity of Soluble Thrombomodulin (ART-123) Burlage,

  2019cites this paper
• Plasma From Patients Undergoing Liver Transplantation Is Resistant to Anticoagulant Activity of Soluble Thrombomodulin

  2019cites this paper
• Recombinant thrombomodulin prevented hepatic ischemia-reperfusion injury by inhibiting high-mobility group box 1 in rats.

  2019cites this paper
• Inhibition of glycogen synthase kinase 3β protects liver against ischemia/reperfusion injury by activating 5′ adenosine monophosphate‐activated protein kinase‐mediated autophagy

  2018cites this paper
• Recombinant Human Soluble Thrombomodulin Attenuates Hepatic Ischemia and/or Reperfusion Injury by Inhibiting Leukocyte Accumulation in Mice With Normal and Fatty Liver.

  2018cites this paper
• Damage-associated molecular patterns in intensive care unit patients with acute liver injuries

  2018cites this paper